Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666295 | 0.85 | MGLL (0.47) | CA1CA2MGLLLMNAHSD17B10 | |
| SCHEMBL976147 | 0.85 | LMNA (0.47) | LMNAHSD17B10AGTR1AGTR2ALDH1A1 | |
| SCHEMBL9235857 | 0.82 | MEN1 (0.42) | LMNAHSD17B10AGTR1AGTR2ALDH1A1 | |
| SCHEMBL9025603 | 0.81 | MEN1 (0.41) | LMNAHSD17B10AGTR1AGTR2ALDH1A1 | |
| SCHEMBL7195878 | 0.80 | LMNA (0.43) | MGLLLMNAAGTR1AGTR2ALDH1A1 | |
| SCHEMBL8323797 | 0.78 | LMNA (0.39) | LMNAHSD17B10AGTR1AGTR2ALDH1A1 | |
| SCHEMBL9025749 | 0.77 | AGTR1 (0.43) | CA1CA2MGLLLMNAHSD17B10 | |
| SCHEMBL7196989 | 0.77 | AGTR1 (0.41) | LMNAHSD17B10AGTR1AGTR2ALDH1A1 | |
| SCHEMBL654077 | 0.77 | AGTR1 (0.39) | LMNAAGTR1AGTR2ALDH1A1TSHR | |
| SCHEMBL3218252 | 0.75 | CYP11B1 (0.33) | CA4CA6CA5ACA7ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931648-A2 | PROCESSES FOR THE SYNTHESIS OF 5-PHENYL -1 TRITYL-1H-TETRAZOLE | Teva Pharmaceutical Industries Ltd. (IL) | 2008-06-18 | — | — | EP | claimed |
| US-20080103312-A1 | Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole | TEVA PHARMACEUTICALS USA, INC. | 2008-05-01 | — | — | US | claimed |
| WO-2008027385-A2 | PROCESSES FOR THE SYNTHESIS OF 5-PHENYL -1 TRITYL-1H-TETRAZOLE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-03-06 | — | — | WO | claimed |
| US-7838683-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-11-23 | — | — | US | disclosed |
| EP-2189457-A1 | Novel synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-05-26 | — | — | EP | disclosed |
| US-20090216026-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2009-08-27 | — | — | US | disclosed |
| EP-2039693-A2 | Novel synthesis of irbesartan | Teva Pharmaceutical Industries Limited (IL) | 2009-03-25 | — | — | EP | disclosed |
| EP-1931648-A2 | PROCESSES FOR THE SYNTHESIS OF 5-PHENYL -1 TRITYL-1H-TETRAZOLE | Teva Pharmaceutical Industries Ltd. (IL) | 2008-06-18 | — | — | EP | disclosed |
| EP-1509517-B1 | NOVEL SYNTHESIS OF IRBESARTAN | TEVA PHARMA (IL) | 2008-06-11 | — | — | EP | disclosed |
| US-20080103312-A1 | Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole | TEVA PHARMACEUTICALS USA, INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008027385-A2 | PROCESSES FOR THE SYNTHESIS OF 5-PHENYL -1 TRITYL-1H-TETRAZOLE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-03-06 | — | — | WO | disclosed |
| US-7301035-B2 | Intermediates for the synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-27 | — | — | US | disclosed |
| US-20070213539-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2007-09-13 | — | — | US | disclosed |
| US-7227026-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-05 | — | — | US | disclosed |
| US-7217825-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-05-15 | — | — | US | disclosed |
| US-20060135780-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2006-06-22 | — | — | US | disclosed |
| US-20060135544-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2006-06-22 | — | — | US | disclosed |
| US-20060128968-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2006-06-15 | — | — | US | disclosed |
| US-7019148-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-03-28 | — | — | US | disclosed |
| US-20040192713-A1 | Novel synthesis of irbesartan | TEVA PHARMACEUTICALS USA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213539-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | CA1 2986/4885CA2 816/4885MGLL 4862/4885 |
| US-20080103312-A1 | Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole | REN, AGTR1, AGTR2 | CA1 2265/4885CA2 475/4885MGLL 4497/4885 |
| US-20060135544-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | CA1 2986/4885CA2 816/4885MGLL 4862/4885 |
| US-20060128968-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | CA1 2986/4885CA2 816/4885MGLL 4862/4885 |
| US-20040192713-A1 | Novel synthesis of irbesartan | REN, AGTR1, AGTR2 | CA1 3252/4885CA2 1121/4885MGLL 4859/4885 |
| US-20060135780-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | CA1 2986/4885CA2 816/4885MGLL 4862/4885 |
| US-20090216026-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | CA1 2986/4885CA2 816/4885MGLL 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.